Search - tctmd.com

Displaying 1 - 3 of 3

Sort: Relevancy | Date

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.